Anti-MUC16 antibody combo to fight metastatic pancreatic cancer
Official title: Anti-MUC16 humanized antibody combination regimen for targeting metastasis in pancreatic cancer
Funded at Sanguine Diagnostics and Therapeutics · NIH-11408229 · Data updated 2026-11-12
A new antibody-based treatment added to standard chemotherapy is being tested to slow or stop the spread of pancreatic cancer in preclinical models.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanguine Diagnostics and Therapeutics NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $399,999 |
| NIH project number | 1R44CA306744-01A1 |
| Project ID | NIH-11408229 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are those with metastatic pancreatic ductal adenocarcinoma or related PDAC biology in the research setting or future clinical trial candidates.
✕Less likely to help
Patients without MUC16 expression or those unlikely to respond to antibody-based strategies may see limited or no benefit.
What this research studies
This program focuses on a humanized antibody regimen that targets MUC16, used together with standard chemotherapy to attack metastatic pancreatic cancer in lab models. The work aims to show that this combo can reduce tumor growth and spread by hitting a specific cancer target. It builds on existing MUC16 tools, including the mAb5E6 antibody, to better understand how these therapies work together. If successful in preclinical studies, it could pave the way for future clinical testing in patients with metastatic PDAC.
Why it matters
Potential benefit: If successful, patients with metastatic pancreatic cancer could have a more effective treatment option that slows progression when combined with current chemotherapy.
How similar studies have gone: Early preclinical data suggest antibody therapies targeting cancer markers can reduce tumor growth and metastasis in other cancers, but human PDAC-targeted antibodies are still being validated.
Where this research is happening
-
Sanguine Diagnostics and Therapeutics
Omaha, United States Active
Researchers
- Principal investigator: Souchek, Joshua James — Sanguine Diagnostics and Therapeutics
- Study coordinator: Souchek, Joshua James
Related research
Other NIH-funded projects on the same topics.
-
Camk2b loss fuels pancreatic cancer spread and immune suppression
A new NIH grant seeks to understand why losing CAMK2B in pancreatic cancer makes the cancer spread more and suppresses immune responses, using advanced mouse models.
-
Cystine-limited stress and pancreatic cancer growth and spread
Aims to understand how pancreatic cancer cells survive when the nutrient cystine is scarce and to find weak spots that could be targeted to slow or stop tumor growth and spread.
-
Understanding what drives metastasis in pancreatic cancer
A researcher at a top cancer center is studying why pancreatic cancer spreads, aiming to identify key factors that could be targeted to stop metastasis.
-
Microbes in pancreatic cancer: where they live and how they affect spread
This research studies how bacteria inside pancreatic tumors and liver metastases might influence cancer growth and spread, with goals that could lead to new ways to treat or manage pancreatic cancer.
-
RHAMM B and pancreatic cancer spread
Researchers are studying RHAMM B to understand how pancreatic cancer spreads and to find new ways to stop it.
-
Nucleic acid scavengers to slow pancreatic cancer spread during therapy
This project tests a new approach that uses special molecules to soak up DNA/RNA fragments released during pancreatic cancer treatment to help prevent cancer spread.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.